Ignite Creation Date:
2024-05-05 @ 11:57 PM
Last Modification Date:
2024-10-26 @ 10:42 AM
Study NCT ID:
NCT01455389
Status:
TERMINATED
Last Update Posted:
2022-03-02
First Post:
2011-10-17
Brief Title:
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Sponsor:
Genprex Inc
Organization:
Genprex Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-02
Start Date Type:
ACTUAL
Primary Completion Date:
2016-10-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-09-28
Completion Date Type:
ACTUAL
First Submit Date:
2011-10-17
First Submit QC Date:
October 17 2011
Study First Post Date:
2011-10-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-11
Last Update Post Date:
2022-03-02
Last Update Post Date Type:
ACTUAL